Compare AWRE & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AWRE | GDTC |
|---|---|---|
| Founded | 1986 | 2018 |
| Country | United States | Singapore |
| Employees | 80 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.6M | 10.4M |
| IPO Year | 1996 | 2021 |
| Metric | AWRE | GDTC |
|---|---|---|
| Price | $1.19 | $0.86 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 31.7K | 13.5K |
| Earning Date | 04-29-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.02 | $0.68 |
| 52 Week High | $2.84 | $3.68 |
| Indicator | AWRE | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 47.72 | 49.10 |
| Support Level | $1.13 | $0.74 |
| Resistance Level | $1.36 | $1.05 |
| Average True Range (ATR) | 0.06 | 0.09 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 35.51 | 53.29 |
Aware Inc provides biometric identity and authentication solutions. Its Awareness Platform transforms biometric data into actionable intelligence, allowing its clients to verify identities and authenticate access and transactions. The company's products span multiple biometric modalities, including fingerprint, face, iris, and voice. It offers: a broad range of biometrics software products and solutions, including platforms like AwareSDK, AwareABIS, AFIX Suite of Products, Awareness Platform, and WebEnroll; software components such as SDKs, APIs, and applications that customers use to develop their systems into more effective solutions; and several program management and software engineering services. Aware earns maximum revenue from the U.S., followed by the UK and the rest of the world.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.